Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase II Pediatric Results A Boost For Replidyne’s Faropenem

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will not make a commitment to pursuing a Phase III trial for the antibiotic until a second-quarter meeting with FDA.

You may also be interested in...



Replidyne Seeks Another Partner Before Conducting New Phase III Orapem Studies

FDA requests four additional studies to reconsider a new NDA for antibiotic candidate that was previously deemed “not approvable.”

Replidyne Seeks Another Partner Before Conducting New Phase III Orapem Studies

FDA requests four additional studies to reconsider a new NDA for antibiotic candidate that was previously deemed “not approvable.”

Replidyne Seeks New Partner For Orapem After Forest Backs Out Of Development

Replidyne said its top priority will be clarifying the regulatory approval process for community antibiotics with FDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS065863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel